A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

NCT03700359 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG: Anlotinib Hydrochloride
DRUG: Lobaplatin
DRUG: Etoposide

Sponsor

The First Affiliated Hospital of Guangzhou Medical University